Development of ctDNA for MRD detection in breast cancer

被引：0
|
作者：
Ozaki, Y. [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Adv Med Dev, Dept Breast Med Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.691
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY26-2
引用
收藏
页码：S1296 / S1296
页数：1
相关论文
共 50 条
  • [31] Plasma-only ctDNA-Guided MRD Detection in Patients with CRC-Response
    Parikh, Aparna R.
    Corcoran, Ryan B.
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6614 - 6615
  • [32] Plasma-only ctDNA-Guided MRD Detection in Patients with CRC-Letter
    Reinert, Thomas
    V. Henriksen, Tenna
    Aleshin, Alexey
    Zimmermann, Bernhard
    Andersen, Claus Lindbjerg
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6613 - 6613
  • [33] Message from the void: MRD analysis from ctDNA
    Heuser, Michael
    Lai, Courteney K.
    BLOOD, 2019, 133 (25) : 2631 - 2633
  • [34] Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
    Nagata, J.
    Nakamura, Y.
    Watanabe, J.
    Akazawa, N.
    Ikeda, M.
    Yokota, M.
    Kato, K.
    Kotaka, M.
    Yamazaki, K.
    Kagawa, Y.
    Yeh, K-H.
    Laliotis, G.
    Jurdi, A.
    Kotani, D.
    Bando, H.
    Taniguchi, H.
    Takemasa, I.
    Kato, T.
    Yoshino, T.
    Oki, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S457 - S457
  • [35] Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, epigenomic assay in patients with early-stage breast cancer - results from the Success A study
    Friedl, Thomas W. P.
    Rack, Brigitte
    Fasching, Peter Andreas
    Hartkopf, Andreas
    Tesch, Hans
    Lorenz, Ralf
    Heinrich, Georg
    Blohmer, Jens-Uwe
    Fehm, Tanja
    Mueller, Volkmar
    Schneeweiss, Andreas
    Beckmann, Matthias
    Ruebner, Matthias
    Harbeck, Nadia
    Pantel, Klaus
    Dustin, Derek
    Cai, Mingyang
    Janni, Wolfgang
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 261 - 261
  • [36] Reference materials for ctDNA-based measurable residual disease (MRD) assay development and validation
    Lowe, Dana Ruminski
    Forson, Benedicta
    Butler, Matthew G.
    Konigshofer, Yves
    Huang, Catherine
    Clement, Omoshile
    Garlick, Russell K.
    Anekella, Bharathi
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery
    Garcia-Murillas, Isaac
    Cutts, Rosalind J.
    Ulrich, Lara
    Beaney, Matthew
    Robert, Marie
    Coakley, Maria
    Bunce, Catey
    WalshCrestani, Giselle
    Hrebien, Sarah
    Kalashnikova, Ekaterina
    Wu, Hsin-Ta
    Dashner, Scott
    Sethi, Himanshu
    Aleshin, Alexey
    Ring, Alistair
    Okines, Alicia
    Smith, Ian E.
    Dowsett, Mitch
    Barry, Peter
    Turner, Nicholas C.
    CANCER RESEARCH, 2022, 82 (04)
  • [38] Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer
    Scandino, Riccardo
    Nardone, Agostina
    Casiraghi, Nicola
    Galardi, Francesca
    Genovese, Mattia
    Romagnoli, Dario
    Paoli, Marta
    Biagioni, Chiara
    Tonina, Andrea
    Migliaccio, Ilenia
    Pestrin, Marta
    Moretti, Erica
    Malorni, Luca
    Biganzoli, Laura
    Benelli, Matteo
    Romanel, Alessandro
    NPJ BREAST CANCER, 2025, 11 (01)
  • [39] Detection of Molecular Residual Disease (MRD) using ctDNA in NSCLC: A Systematic Review and Meta-Analysis
    Galvano, A.
    Gristina, V.
    Insalaco, L.
    La Mantia, M.
    Perez, A.
    Barraco, N.
    Castellana, L.
    Bono, M.
    Cusenza, S.
    Castiglia, M.
    Lisanti, C.
    Cutaia, S.
    Ricciardi, M.
    Sardo, D.
    Inguglia, S.
    Rizzo, S.
    Bazan, V.
    Russo, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S278 - S278
  • [40] Haematological cancer: Improved sensitivity in MRD detection
    Romero D.
    Nature Reviews Clinical Oncology, 2018, 15 (3) : 134 - 134
12345